Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population

References

• WHO. Influenza (Seasonal); 2023. [cited 2023 June28]. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
   Google Scholar
• Bossuyt N, Thomas I, Barbezange C, et al. Surveillance des infections à influenza. Rapport épidémiologique saison 2018-2019. Brussels: Sciensano; 2019.
   Google Scholar
• Beutels P, Vandendijck Y, Willem L, et al. Seasonal influenza vaccination: prioritizing children or other target groups? Belgium: Belgian Health Care Knowledge Centre (KCE); 2013.
   Google Scholar
• Meier CR, Napalkov PN, Wegmüller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000;19(11):834–842. doi:10.1007/s100960000376
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Nombre de séjours hospitaliers par diagnostic ICD-10 - RHM. Brussels: Ministry of Health; 2021.
   Google Scholar
• WHO. ICD -10 version: 2016. Geneva: Switzerland: World Health Organization; 2022.
   Google Scholar
• Giacchetta I, Primieri C, Cavalieri R, et al. The burden of seasonal influenza in Italy: a systematic review of influenza-related complications, hospitalizations, and mortality. Influenza Other Respir Viruses. 2022;16(2):351–365. doi:10.1111/irv.12925
   PubMed Web of Science ®Google Scholar
• Statbel. Mortality, life expectancy and causes of death. 2023 [cited 2022 Nov 15]. Available from: https://stabel.fgov.be/fr/themes/population
   Google Scholar
• KCE. Task force therapeutics. Antivirals against influenza (flu). Brussels: KCE; 2022.
   Google Scholar
• WHO. Europe. Types of seasonal influenza vaccine. Geneva: Switzerland: World Health Organization; 2023.
   Google Scholar
• Ministry of Health. Superior health council. Seasonal influenza: winter season 2022-2023. Report No.: 9699. Brussels: Ministry of Health; 2022.
   Google Scholar
• Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine. 2009;27(37):5043–5053. doi:10.1016/j.vaccine.2009.06.032
   PubMed Web of Science ®Google Scholar
• Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-induced immunity. Cell Immunol. 2020;348:103998. doi: 10.1016/j.cellimm.2019.103998
   PubMed Web of Science ®Google Scholar
• Gärtner BC, Weinke T, Wahle K, et al. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective – a systematic review of recently published literature on real-world data. Vaccine. 2022;40(22):2999–3008. doi:10.1016/j.vaccine.2022.04.019
   PubMed Web of Science ®Google Scholar
• INAMI/RIZIV. Médicaments remboursables par l’assurance soins de santé. 2022. [cited 2023 Jan 15]. Available from: https://webappsa.riziv-inami.fgov.be/SSPWebApplicationPublic/fr/Public/ProductSearch
   Google Scholar
• Jacob J, Biering-Sørensen T, Holger Ehlers L, et al. Cost-effectiveness of vaccination of older adults with an MF59®-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in Denmark, Norway, and Sweden. Vaccines. 2023;11(4):753. doi:https://doi.org/10.3390/vaccines11040753
   Web of Science ®Google Scholar
• Kohli MA, Maschio M, Cartier S, et al. The cost-effectiveness of vaccination of older adults with an MF59-adjuvanted quadrivalent influenza vaccine compared to other available quadrivalent vaccines in Germany. Vaccines. 2022 25;10(9):1386. doi: 10.3390/vaccines10091386
   PubMed Web of Science ®Google Scholar
• Calabrò GE, Boccalini S, Panatto D, et al. The new quadrivalent adjuvanted influenza vaccine for the Italian elderly: a health technology assessment. Int J Environ Res Public Health. 2022;19(7):4166. doi:10.3390/ijerph19074166
   PubMed Web of Science ®Google Scholar
• Fochesato A, Sottile S, Pugliese A, et al. An economic evaluation of the adjuvanted quadrivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine in the Spanish older adult population. Vaccines. 2022;10(8):1360. doi:10.3390/vaccines10081360
   Web of Science ®Google Scholar
• Cai R, Gerlier L, Eichner M, et al. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany. J Med Econ. 2021;24(1):490–501. doi:10.1080/13696998.2021.1908000
   PubMed Web of Science ®Google Scholar
• Dolk C, Eichner M, Welte R, et al. Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model. Pharmacoeconomics. 2016;34(12):1299–1308. doi:10.1007/s40273-016-0443-7
   PubMed Web of Science ®Google Scholar
• Van Bellinghen LA, Meier G, Van Vlaenderen I, et al. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9(6):e98437. doi: 10.1371/journal.pone.0098437
   PubMed Web of Science ®Google Scholar
• Alvarez FP, Chevalier P, Borms M, et al. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal. J Med Econ. 2023;26(1):710–719. doi:10.1080/13696998.2023.2194193
   PubMed Web of Science ®Google Scholar
• WHO. WHO guide for standardization of economic evaluations of immunization programmes. 2nd ed. Geneva: Switzerland: World Health Organization; 2019.
   Google Scholar
• Annemans L, Beutels P, Bloom DE, et al. Economic evaluation of vaccines: belgian reflections on the need for a broader perspective. Value Health. 2021;24(1):105–111. doi:10.1016/j.jval.2020.09.005
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Van De Sande S, et al. Belgian guidelines for economic evaluations and budget impact analyses. 2nd ed. Belgium: Belgian Health Care Knowledge Centre (KCE); 2012. KCE report 183.
   Google Scholar
• Ruiz-Aragón J, Márquez-Peláez S, Gani R, et al. Cost-effectiveness and burden of disease for adjuvanted quadrivalent influenza vaccines compared to high-dose quadrivalent influenza vaccines in elderly patients in Spain. Vaccines. 2022;10(2):176. doi:10.3390/vaccines10020176
   Web of Science ®Google Scholar
• Chit A, Becker DL, DiazGranados CA, et al. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. Lancet Infect Dis. 2015;15(12):1459–1466. doi:10.1016/S1473-3099(15)00249-2
   PubMed Web of Science ®Google Scholar
• WHO. Influenza. Geneva: Switzerland: World Health Organization; 2022.
   Google Scholar
• Somes MP, Turner RM, Dwyer LJ, et al. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: a systematic review and meta-analysis. Vaccine. 2018;36(23):3199–3207. doi:10.1016/j.vaccine.2018.04.063
   PubMed Web of Science ®Google Scholar
• Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–951. doi:10.1016/S1473-3099(16)00129-8
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645. doi:10.1056/NEJMoa1315727
   PubMed Web of Science ®Google Scholar
• Coleman BL, Sanderson R, Haag MDM, et al. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813–823. doi:10.1111/irv.12871
   PubMed Web of Science ®Google Scholar
• Sciensano. HISIA: belgian health interview survey -interactive analysis. 2018 [cited 2022 Nov 15]. Available from: https://www.sciensano.be/en/projects/health-interview-survey/hisia
   Google Scholar
• Mao Z, Li X, Korsten K, et al. Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in european community-dwelling older adults. J Infect Dis. 2022;226(Suppl 1):S87–S94. doi:10.1093/infdis/jiac069
   PubMed Web of Science ®Google Scholar
• Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688. doi:10.1183/13993003.02688-2020
   PubMed Web of Science ®Google Scholar
• Bilcke J, Coenen S, Beutels P, et al. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLoS One. 2014;9(7):e102634. doi: 10.1371/journal.pone.0102634
   PubMed Web of Science ®Google Scholar
• Marbaix S, Peetermans WE, Verhaegen J, et al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLoS One. 2018;13(7):e0199427. doi:10.1371/journal.pone.0199427
   PubMed Web of Science ®Google Scholar
• Fu M, Kontogeorgos S, Thunström E, et al. Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 2014. Sci Rep. 2022;12(1):1810. doi:10.1038/s41598-022-05951-z
   PubMed Web of Science ®Google Scholar
• Federal Planning Bureau. Population projections 2022-2070. Brussels: Federal Planning Bureau; 2023.
   Google Scholar
• Sciensano. Influenza. Numbers [cited February 2023]. Available from:https://www.sciensano.be/en/node/464
   Google Scholar
• Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345–353. doi:10.1056/NEJMoa1702090
   PubMed Web of Science ®Google Scholar
• Boehme AK, Luna J, Kulick ER, et al. Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018;5(4):456–463. doi:10.1002/acn3.545
   PubMed Web of Science ®Google Scholar
• Van Wilder L, Charafeddine R, Beutels P, et al. Belgian population norms for the EQ-5D-5L, 2018. Qual Life Res. 2022;31(2):527–537. doi:10.1007/s11136-021-02971-6
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Lanitis T, Lieven A, et al. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium. Clin Drug Investig. 2014;34(10):709–721. doi:10.1007/s40261-014-0224-z
   PubMed Web of Science ®Google Scholar
• Statbel. Consumer health index. Brussels: Statbel; 2023.
   Google Scholar
• INAMI/RIZIV - Ministry of Health. Banque nationale de données diagnostic médical/soins & coût. Cellule Technique de traitement de données relatives aux hôpitaux. 2020 [cited 2023 Jan 15]. Available from: https://tct.fgov.be
   Google Scholar
• INAMI/RIZIV. Nomensoft: nomenclature et pseudonomenclature des prestations de santé. 2023 [cited 2023 Jan 20]. Available from: https://webappsa.riziv-inami.fgov.be/Nomen/fr/search
   Google Scholar
• INAMI/RIZIV. Circulaire aux etablissements hospitaliers CIRC. HOP. 2022. [cited 2023 Feb 2023]. Available from: https://www.inami.fgov.be/fr/professionnels/etablissements-services/hopitaux/Pages/default.aspx
   Google Scholar
• Beutels P, Blommaert A, Hanquet G, et al. Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood. 1st. Belgium: Belgian Health Care Knowledge Centre (KCE); 2011.
   Google Scholar
• Joint Committe on Vaccination and Immunisation. Advice on influenza vaccines for 2023/24 2022 [updated Nov 2022; 20 May 2023]. Available from: https://app.box.com/s/t5ockz9bb6xw6t2mrrzb144njplimfo0/file/1079253178131.
   Google Scholar
• Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2022-23 Influenza Season. MMWR Recomm Rep. 2022 Aug 26;71(1):1–28. doi: 10.15585/mmwr.rr7101a1
   PubMedGoogle Scholar
• Volpe M, Battistoni A. What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season? Eur Heart J Suppl. 2023;25(Supplement_A):A1–A4. doi: https://doi.org/10.1093/eurheartjsupp/suac109
   PubMedGoogle Scholar
• Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine. 2021;39(Suppl 1):A6–A14. doi: 10.1016/j.vaccine.2020.09.048
   PubMed Web of Science ®Google Scholar
• Hanquet G, Benahmed N, Castanares-Zapatero D, et al. Report on post-intensive care syndrome (PICS) for general practitioners. COVID-19 KCE contributions. Belgium: Belgian Health Care Knowledge Centre (KCE); 2020.
   Google Scholar
• Buckley BS, Henschke N, Bergman H, et al. Impact of vaccination on antibiotic usage: a systematic review and meta-analysis. Clin Microbiol Infection. 2019 Oct;25(10):1213–1225.
   PubMed Web of Science ®Google Scholar